A breakthrough technology for combination cancer therapy
Enabling the Expanded Universe of Cancer Therapy
Immuno fluorescence imaging technology powered by nanoparticles
Single Cell Multiplex Functional Screening with Patient Derived Cells
Genomics fails to capture the complexity and heterogeneity of patient cellular response in the majority of cancer drug targets. CytoImage’s multiplex nano particle imaging technology allows rapid and precise assessment of phenotypic functional response for each cell, each individual, and across study cohorts. The technology provides insights into drug sensitivity and resistance unobtainable with current methods.
The expanding universe of cancer targets poses daunting challenges for developers of combination precision therapy.
The CytoImage functional precision medicine platform identifies the most promising combination therapy conditions ex vivo and quantifies patient response in situ.
How it works
3 days from sample receipt to
cancer therapy response
CytoImage delivers the potential of combination precision medicine
More predictive than xenograft models, more sensitive than flow cytometry, more precise than bulk cell sensitivity assays, and all in less time.
Proprietary Technology, Peer reviewed publications, real world evidence
Designed and Developed for Clinical Research
The CytoImage platform was developed over 7 years in a world-leading cancer research center and recently employed by biopharma drug developers.
Ready to learn more about the power of single-cell
functional precision medicine?
Empower your combination therapy pipeline.
Reach out to learn more